Aminoacetamide acyl guanidines as β-secretase inhibitors

Details Aminoacetamide acyl guanidines as β-secretase inhibitors Aminoacetamide acyl guanidines as β-secretase inhibitors

2007-09-25

2007-09-25

Anderson, Rebecca (Department: 1626)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C514S210200, C514S217090, C514S406000, C514S326000, C514S378000, C514S340000, C514S341000, C548S373100, C548S206000, C548S248000, C544S367000, C546S209000

Reexamination Certificate

active

11471104

ABSTRACT:
There is provided a series of substituted acyl guanidines of Formula (Ik)or a stereoisomer; or a pharmaceutically acceptable salt thereof, wherein R2, R3, R4, R5, R25, R26and R27as defined herein, their pharmaceutical compositions and methods of use. These compounds inhibit the processing of amyloid precursor protein (APP) by β-secretase and, more specifically, inhibit the production of Aβ-peptide. The present disclosure is directed to compounds useful in the treatment of neurological disorders related to β-amyloid production, such as Alzheimer's disease and other conditions affected by anti-amyloid activity.

REFERENCES:
patent: 6849733 (2005-02-01), Hong et al.
Greenberg, Neurology, vol. 51(3), 1998, p. 690-694.
Medical Encyclopedia: Senile cerebral amyloid angiopathy, retrieved from the Internet on Mar. 20, 2007, <http://www.nlm.nih.gov/medlineplus/ency/article/000719.htm>.
Medical Encyclopedia: Down syndrome, retrieved from the Internet on Mar. 20, 2007, <http://www.nlm.nih.gov/medlineplus/ency/article/000997.htm>.
Jennings, L.D., et al., “Acylguanidines as Inhibitors of BACE-1: Variation of pyrrole ring substituents extending into the S1 and S3 pockets”,Abstracts of Papers, 230thACS National Meeting, Washington, D.C., (2005).
Hussain, I. et al., “Identification of a Novel Aspartic Protease (Asp 2) as β-Secretase”,Mol. Cell. Neurosci, (1999) 14: 419-427.
Lin, X. et al., “Human aspartic protease memapsin 2 cleaves the β-secretase site of β-amyloid precursor protein”, Proceedings of the National Academy of Sciences of the USA, (2000) 97: 1456-1460.
Luo, Y., et al., “Mice deficient in BACE1, the Alzheimer's β-secretase, have normal phenotype and abolished β-amyloid generation”,Nature Neuroscience(2001) 4: 231-232.
Roberds, S.L. et al., “BACE knockout mice are healthy despite lacking the primary β-secretase activity in brain: implications for Alzheimer's disease therapeutics”,Human Molecular Genetics(2001) 10: 1317-1324.
Seiffert, D.; et al., “Presenilin-1 and -2 are molecular targets for γ-secretase inhibitors”,J. Biol. Chem.(2000) 275, 34086-34091.
Selkoe, D. J., “Alzheimer's Disease: Genes, Proteins, and Therapy”,Physiol. Rev.(2001) 81, 741-766.
Selkoe, D. J., “Biochemical Analyses of Alzheimer's Brain Lesions lead to the Identification of αβ and its Precursor”,Ann. Rev. Cell Biol.(1994) 10: 374-403.
Sinha, S., et al., “Purification and cloning of amyloid precursor protein β-secretase from human brain”,Nature(London) (1999) 402: 537-540.
Solvibile, W.R., et al., “Thiophene acyl guanidines as BACE1 Inhibitors”,Abstracts of Papers, 230thACS National Meeting, Washington, D.C., (2005).
Stock, J.R., et al., “Acylguanidines as small molecule BACE1 Inhibitors: Initial exploration of S1 and S2'pockets”,Abstracts of Papers, 230thACS National Meeting, Washington, D.C., (2005).
Sukhdeo, M.N., et al., “Acylguanidines as small molecule BACE1 Inhibitors: Optimization of the S1'region”,Abstracts of Papers, 230thACS National Meeting, Washington, D.C., (2005).
Thal, D. R., et al., “Two types of Sporadic Cerebral Amyloid Angiopathy”,J. Neuropath. and Exper. Neurology(2002) 61: 282-293.
Vassar, R., et al., “β-Secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE”,Science(1999) 286: 735-741.
Walsh, D. M., et al., “Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo”,Nature(2002) 416, 535-539.
Wolfe, M. S., “Secretase Targets for Alzheimer's Disease: Identification and Therapeutic Potential”,J. Med. Chem.(2001) 44, 2039-2060.
Yan, R. et al., “Membrane-anchored aspartyl protease with Alzheimer's disease β-secretase activity”,Nature(1999) 402: 533-537.
Zhou, P., et al., “Acylguanidines as small molecule BACE1 Inhibitors: Exploration of the S1 pocket”,Abstracts of Papers, 230thACS National Meeting, Washington, D.C., (2005).

Affiliated with

Also associated with

Rating

Aminoacetamide acyl guanidines as &#x3b2;-secretase inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Aminoacetamide acyl guanidines as &#x3b2;-secretase inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Aminoacetamide acyl guanidines as &#x3b2;-secretase inhibitors will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3792775